Conferences  >  Medicine & Healthcare  >  Surgery  >  Switzerland

ESMO - European Society for Medical Oncology

The ESMO Sarcoma and Rare Cancers Congress 2026 will once again serve as a premier forum for sharing groundbreaking research, novel treatment strategies, and fostering collaborations to drive progress in this crucial area of oncology. Join us from 12–14 March 2026 in the charming city of Lugano, Switzerland, renowned for its stunning lakeside views and rich cultural heritage. The scientific and educational programme will explore the latest advancements in diagnosis, treatment, biology, and molecular classification of rare solid tumours, ensuring a comprehensive update on the evolving landscape of these complex diseases. Attendees can engage in Abstract-related sessions, educational lectures, Multidisciplinary Tumour Boards, Special Sessions, Guidelines discussions, and dedicated Young Oncologists sessions, all designed to enhance knowledge and foster interactive discussions. Whether you are a clinician, researcher, healthcare professional, industry expert, or patient advocate, this congress offers a unique opportunity to connect, learn, and contribute to the future of sarcoma and rare cancer care.

ESMO Meetings Operations Team;     Phone: [+41 91 97 31 946];     Email: meetings@esmo.org

Sarcoma biology, Rare cancers, Tumour microenvironment, Molecular diagnostics, Genomic profiling, Precision oncology, Biomarkers of response, Immunotherapy in sarcomas, Targeted therapy, Novel drug development, Clinical trials phase I, Clinical trials phase II, Clinical trials phase III, Multimodal therapy, Resistance mechanisms, Long-term survivorship, Real-world evidence, Surgery, Radiation therapy, Systemic therapy, Chemotherapy, Targeted agents, Immunomodulators, CAR T-cell therapy, Checkpoint inhibitors, Antiangiogenic therapy, Gene therapy, Combination therapies, Soft tissue sarcoma, Bone sarcoma, GIST, Liposarcoma, Leiomyosarcoma, Undifferentiated pleomorphic sarcoma, Ewing sarcoma, Osteosarcoma, Rhabdomyosarcoma, Synovial sarcoma, Rare mesenchymal tumours, Quality of life, Patient-reported outcomes, Survivorship, Toxicity management, Side effects, Late effects, Palliative care, Patient access, Health equity, Cost effectiveness, Health policy, Imaging techniques, MRI, PET-CT, Functional imaging, Liquid biopsy, Bioinformatics, AI, Single-cell sequencing, Molecular subtyping, Pathology standards, Abstract submission, Late breaker, Keynote lecture, Workshops, Poster sessions, Multidisciplinary teams, Collaborative networks, Guidelines, Consensus statements, Regulatory framework

Oncology,    Clinical pathology